Nierenwirksame Arzneimittel
- 24 February 2026
- book chapter
- Published by Springer Nature
- p. 689-699
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Finerenone and Kidney Outcomes in Patients With Heart FailureJACC, 2024
- Kidney and heart failure outcomes associated with SGLT2 inhibitor useNature Reviews Nephrology, 2022
- Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from DenmarkJournal of the American Academy of Dermatology, 2018
- A reappraisal of loop diuretic choice in heart failure patientsAmerican Heart Journal, 2015
- Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HFCurrent Heart Failure Reports, 2011
- Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line AgentsJAMA, 2003
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failureThe American Journal of Medicine, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999